NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…
On Twitter, @ACRheumDC Puts Advocacy Updates at Your Fingertips
The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.
RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett
At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
ACR Advocates Against VIVIO Interference in Patient Care Decisions
The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.
Spring Review of 2021 State Legislative Progress
Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.
Validation of Proposed Remission and Completion Criteria for Gout Treatment
10 Tips to Master E/M Coding Changes
Learn to properly use the revised CPT codes to document your time and medical decision making during patient visits to help ensure your practice is appropriately remunerated.
Insights into the Symptom Heterogeneity of Post-Treatment Lyme Disease
New research into the symptom heterogeneity of patients with post-treatment Lyme disease may serve as a framework to create targeted interventions or novel treatments for these patients.
RA Shortens Life Expectancy of Patients with RA & Increases Healthcare Costs
RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.
COVID-19 Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
FDA News Release—On April 16, saying that alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and…
- « Previous Page
- 1
- …
- 150
- 151
- 152
- 153
- 154
- …
- 816
- Next Page »